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Abstract
The gluten analysis of foods has long had limitations, which have precluded food standards
authorities from issuing standards for gluten-free foods based on final gluten content. The Codex
Alimentarius and the Food and Drug Administration have taken steps towards such standards in
which they favour the R5-enzyme-linked immunosorbent assay for gluten analysis. If this method is
to be widely employed, its limitations should be recognised. Above all, it should be noted the ability
of R5-enzyme-linked immunosorbent assay, and other methods, to measure gluten's toxicity
toward celiac disease patients is not validated clinically. Gluten is a complex mixture of proteins
and its toxicity is not fully understood. Analytical methods are a valuable tool in the definition of
gluten-free foods, but they should be employed with appropriate caveats in ensuring the safety of
the foods.
Introduction
Celiac disease (CD) is chronic gastrointestinal inflamma-
tion caused by an aberrant immune response to dietary
gluten [1]. It is treated by life-long adherence to a gluten-
free (GF) diet.
Speciality GF foods cater for CD patients. ELISA assays
have long been used to monitor these foods, but the
methods have had limitations which, until recently, have
prevented them gaining acceptance as the basis for official
GF standards [2,3]. The analysis of gluten is challenging
because gluten is a mixture of water-insoluble proteins,
derived from wheat, barley or rye grain, which in commer-
cial foods, is within a range of matrices and is modified
variously by heat and processing [4].
Commercial methods of gluten analysis are based on the
ELISA, employing an initial extraction step to solubilise
gluten from food samples. The limitations and efficiencies
of these methods for the testing of GF foods were reviewed
previously [4].
New improved gluten ELISAs have since appeared on the
market [5,6] and others are in development [7,8]. The
commercial R-ELISA [5] has been deemed sufficiently reli-
able and sensitive to support standards for GF foods based
on final gluten content [9]. If the method is to be widely
employed, its limitations should be recognised so the
method is used correctly.
Herein, I critically examine the basis of the R5-ELISA and
other recent ELISA methods of gluten analysis.
Discussion
Defining gluten
Gluten is a scientifically imprecise term and its definition
varies, even when GF foods are concerned. Herein, the
current Codex definition of gluten is employed, which is
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'a protein fraction from wheat, rye, barley, oats or their
crossbred varieties and derivatives thereof, to which some
people are intolerant and that is insoluble in water and
0.5 M NaCl' [9]. This definition is similar to that recently
proposed by the FDA, 'the proteins that naturally occur in
a prohibited grain and that may cause adverse health
effects in persons in celiac disease' [10].
Alternatively, gluten is sometimes defined by its solubility
only, a feature which derives from the high proline and
glutamine content of the native gluten proteins. For exam-
ple, 'a protein fraction of wheat, rye or barley insoluble in
water or a solution of 0.5 M NaCl' [4]. Such a definition is
not used here because it does not support meaningful dis-
cussions concerning food safety. (Some food processing
procedures increase gluten's solubility, but do not neces-
sarily diminish the protein fraction's harmful effect).
Demonstrating gluten's toxicity
Demonstrating intolerance to gluten is a complex endeav-
our. The toxicity of gluten in CD stems from an immune
response involving both innate and adaptive systems [1].
No model is available to replicate the response, although
rhesus macaques were recently proposed [11]. The dem-
onstration of gluten intolerance depends on in vivo chal-
lenge studies.
CD has a highly variable presentation [1] and symptoms
are considered unreliable as an indicator of active disease.
The defining indicator of gluten-induced damage in CD is
histopathology of the mucosa of the small intestine [12].
It only develops in response to ongoing gluten exposure,
which means the investigation of gluten intolerance faces
design and ethical hurdles. Other factors associated with
CD hinder representative studies. They include the heter-
ogeneous presentation of disease, a high rate of under-
diagnosis [1] and the lifestyle challenges of a truly GF diet
[13].
Defining gluten-free foods
In many circles, a zero tolerance approach to gluten in GF
foods is considered impractical. With derivatives of wheat,
and to a lesser extent barley, used widely in mainstream
food channels, GF foods are susceptible to contamina-
tion, even when produced in dedicated facilities. Some GF
foods in Europe are even based on wheat-starch [3] which,
though processed to remove gluten, contains gluten resi-
dues. However, many GF foods are entirely free of gluten-
containing grains [14] and they are available throughout
Europe. Preventative measures to minimise contamina-
tion are employed by GF manufacturers which, in some
cases, are very strict. For example, a core group of manu-
facturers not only exclude all gluten-containing grains
from their foods and use dedicated facilities, they also
heed the provenance of all their ingredients.
In efforts to reach a universal definition of GF foods, stud-
ies have aimed to define safe threshold gluten for CD
patients through in vivo challenge studies. While it
remains limited, the evidence base in this area has
strengthened in recent years [15]. It appears the extent to
which gluten must be excluded from the diet varies
between CD individuals [12,15] with highly sensitive
individuals difficult to study. They do not tolerate [12],
and are possibly deterred by, an extended gluten chal-
lenge.
Guidelines for specialty GF foods vary between regulatory
authorities. The FDA recently proposed draft GF standards
for the first time, which are based on final gluten content
[10]. Codex is in the final stages of approving similar
standards [2,9]. The draft standards permit trace gluten in
GF foods, but aim to keep total dietary gluten well below
levels generally accepted as safe for CD patients. They
allow ingredients derived from gluten-containing grains
in the foods, providing the ingredients have been proc-
essed to remove gluten and prescribed limits are met.
In addition, Codex has had standards since 1981, which
define GF foods according to the nitrogen content of raw
ingredients [16]. These standards are only applicable to
GF foods with ingredients derived from wheat, barley or
rye.
The Codex has endorsed the R5-ELISA as a means of
upholding GF standards based on final gluten content [9].
The FDA has tentatively endorsed the method and
acknowledges that future methods including other ELI-
SAs, may prove useful in the area [10]. In light of such sig-
nificant endorsement, it is important to consider the
remaining limitations of gluten analysis by ELISA.
The basis for gluten's toxicity
In vitro, and to a lesser extent, in vivo methods have been
useful in dissecting the basis for gluten's immunotoxicity.
Activation of CD4(+) T cells in the small intestinal
mucosa by gluten peptides released by digestive enzymes
is a key event in CD [17]. A direct effect from other gluten
peptides on the intestinal epithelium has a role in inflam-
mation [17]. Autoantibodies are associated with active
CD and their role in pathogenesis is currently an active
area of research, eg. [18].
Multiple peptides are implicated in T cell stimulation,
present in both major fractions of gluten (in wheat these
fractions are the gliadins and glutenins) [17]. A single
peptide located within a region resistant to digestive
enzymes is the immunodominant portion of the gluten
subfraction, α-gliadin, at least in adult patients [19,20].
The full potency of this peptide, and that of others, is
dependent on its modification by a tissue transglutami-Plant Methods 2008, 4:26 http://www.plantmethods.com/content/4/1/26
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nase within the intestinal mucosa. The enzyme introduces
a negative charge into the peptide, which enhances class II
MHC binding on antigen-presenting cells.
The crucial role of T cell activation in disease pathogenesis
is evident from the association of CD with class II MHC
genotype. Over 90% of patients are positive for the HLA
DQ2 heterodimer with the remainder positive for HLA
DQ8 [17]. The peptides stimulatory to T cells in HLA DQ8
individuals appear to be distinct from those of the HLA
DQ2 model [21].
The bases of recent gluten ELISAs
The commercial R5-ELISA is hailed as a significant
advance in the area of gluten detection [22]. Nonetheless,
developments in the area continue. The bases of the R5-
ELISA and other recent methods are examined here. Ear-
lier gluten ELISAs are not included because they are
already appraised in detail [4].
The R5-ELISA [5] and subsequent methods [7,8] are based
on monoclonal antibodies which target sequences charac-
teristic of peptides stimulatory to T cells. The latest meth-
ods [7,8] have highest specificity for gliadin peptides of
known immunodominance in HLA DQ2 patients, in par-
ticular the well-characterised α-gliadin peptide. One
method also has demonstrated cross-reactivity with a glia-
din peptide which invokes an innate immune response
[8].
The strategy of targeting immunogenic peptides with a
gluten ELISA aims for an analytical method, which acts as
an indicator of food toxicity to CD patients. It contrasts
with the strategy of an earlier, but widely-used gluten
ELISA [23] which targets the most heat-stable subfraction
of gliadin, the ω-gliadins.
It should be noted the gluten proteins are not necessarily
intact when present in food. The original version of the
R5-ELISA and the anti-ω-gliadin ELISA employ a sand-
wich format, which is unable detect small gluten frag-
ments [24]. The latest R5-ELISA, together with other
recent methods, employs a competitive format, which
enables detection of gluten peptides containing single
epitopes and therefore is suitable against highly degraded
protein. At least in sandwich form, the R5-ELISA is consid-
ered more sensitive than the anti-ω-gliadin ELISA and bet-
ter at detecting barley gluten [2,24]. An inability to detect
barley and rye sequences is a weakness of another
recently-developed commercial gluten ELISA [6,25].
Though commercially available, the competitive R5-
ELISA is not yet trialled as extensively as the sandwich R5-
ELISA. The abilities of the sandwich R5-ELISA and the
anti-ω-gliadin to detect the gluten proteins in food were
reviewed recently, and the merits of the competitive R5-
ELISA considered [24].
All gluten ELISAs use a standard of native gliadin [3,4].
The contribution of the glutenins toward gluten measure-
ments is estimated, based on the assumption that both
fractions of gluten are present in equal amounts.
The relationship between gluten measurements and the 
toxicity of food to CD patients
It should be noted that the relationship between ELISA
measurements of gluten in food and the toxicity of the
foods toward CD patients is not directly investigated. No
gluten ELISA has been evaluated through clinical trials.
The relationship has been explored to a limited extent
with a bioassay employing T cells isolated from CD
patients [7].
Thus, the capabilities of ELISA methods to ensure the GF
status of foods are assumed, combining analytical estima-
tions of gluten in food with knowledge on daily safe
threshold levels of gluten and current understanding of its
toxicity toward CD patients.
Remaining limitations of gluten ELISAs
Notwithstanding the advantages of recent methods, the
assessment of the safety of GF foods for CD patients based
on gluten analysis by ELISA is not clearcut. The multiple
challenges [4] associated with the testing of GF foods are
not completely surmounted by the methods. Uncertain-
ties remain regarding (1) the quantitative measurement of
gluten in foods and (2) analytical-based predictions of
food toxicity to CD patients.
Perhaps the most intractable aspect of gluten analysis is
the accurate standardisation of measurements. The most
soluble half of wheat gluten, gliadin, has been deemed the
best standard for gluten measurements, however it may
not accurately represent gluten in food in every instance.
Gluten's precise composition varies between species and
cereal variety. In addition, the food industry uses techno-
logical procedures in the preparation of ingredients and
foods, which modify gluten physically, chemically or
enzymatically. These modifications, as well as matrix
effects associated with food ingredients, may affect glu-
ten's solubility, its intermolecular associations, not to
mention the availability, and even the sequence, of its
epitopes. These factors conceivably impact on gluten anal-
ysis by ELISA protocols, during extraction and/or immun-
odetection. To illustrate the vagaries associated with the
standardisation of gluten measurements, gliadin is no
longer considered ideal as a standard for measuring bar-
ley-derived gluten with the R5-ELISA [24].Plant Methods 2008, 4:26 http://www.plantmethods.com/content/4/1/26
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It is practically impossible to analyse the gluten of com-
mercial foods in a controlled fashion because the foods
are so various and their exact composition is unknown. In
trials of the R5-ELISA [5,26], thousands of commercial GF
foods were analysed, their gluten content estimated
against a pure native gliadin standard. The validity of this
approach in establishing the method's reliability can be
challenged because the approach does show whether glu-
ten in the foods evades detection in some instances. Nor
is it able to reveal whether non-specific antibody interac-
tions are occurring and leading to a skewing of ELISA val-
ues. Controlled experiments were included in the trials
[5], however they involved relatively simple foods spiked
with native gliadin only, which, arguably, do not reflect
the diversity of commercial foods.
Indeed, a subsequent study [25] suggests that the R5-
ELISA fails to detect some forms of gluten, at least when
employed in the sandwich format. The sandwich R5-
ELISA yielded lower gluten values on beer samples than
the competitive R5-ELISA. This difference was attributed
to an inability of the sandwich R5-ELISA to detect hydro-
lysed gluten, however the experiments were insufficiently
controlled to show that the competitive R5-ELISA reliably
detected all gluten in the commercial samples tested.
The use of a gliadin standard for gluten measurements
may also be challenged on the basis it overlooks the glu-
tenin fraction of gluten. Formerly, the contribution of this
less soluble fraction to gluten toxicity was unclear [4],
however glutenin peptides are now known to be involved
in T cell activation in CD patients [17]. Being highly insol-
uble, the glutenins may persist throughout processing
procedures, which eliminate the gliadins [27]. Thus, it is
debatable whether a gluten detection method is capable
of indicating food toxicity, using a gliadin standard only.
Other weaknesses can be found in the theory behind glu-
ten ELISAs. Gluten's toxicity is related to its quality as well
as its quantity. The immunogenicity of gluten proteins
varies according to influences such as cereal variety and
food processing procedures [2]. Most notably, deamida-
tion has implications for food safety [28]. Deamidated
gluten is detected inefficiently by the R5-ELISA [29], yet
may have heightened toxicity in some instances.
Conclusion
Gluten ELISAs are able to detect gluten contamination in
foods in many instances and are a valuable tool in the
analysis of GF foods. However, they are not clinically val-
idated as an indicator of food toxicity toward CD patients
and analytical-based predictions of food toxicity are not
straightforward. The methods cannot on their own ensure
the safety of GF foods, but must be employed with appro-
priate caveats. False reliance on the methods is to be
avoided, if official standards for GF foods based on final
gluten content are widely adopted.
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